ロード中...
New developments in acne treatment: role of combination adapalene–benzoylperoxide
The fixed-dose combination adapalene 0.1%/benzoylperoxide 2.5% (A/BPO) was introduced as an acne vulgaris therapeutic in 2007. It combines anti-inflammatory, keratolytic, comedolytic, and antibacterial properties. Thus, it addresses several pathophysiological factors involved in the pathophysiology...
保存先:
| 出版年: | Ther Clin Risk Manag |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5055040/ https://ncbi.nlm.nih.gov/pubmed/27757036 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S94062 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|